What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

December 8, 2025Blood

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals that allo-HCT outcomes in BPDCN patients indicate potential benefit from tagraxofusp therapy.

Allogeneic hematopoietic stem cell transplantation in BPDCN patients may improve outcomes over standard treatments.
The study reports that 63% of patients were alive after a median follow-up of 27 months, indicating potential effectiveness.
Observational analysis of data from the BPDCN international registry assessed results of various treatment strategies.
Highlighting the potential importance of optimizing access to tagraxofusp followed by allo-HCT for better patient outcomes.

Badikyan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals that allo-HCT outcomes in BPDCN patients indicate potential benefit from tagraxofusp therapy.

Allogeneic hematopoietic stem cell transplantation in BPDCN patients may improve outcomes over standard treatments.
The study reports that 63% of patients were alive after a median follow-up of 27 months, indicating potential effectiveness.
Observational analysis of data from the BPDCN international registry assessed results of various treatment strategies.
Highlighting the potential importance of optimizing access to tagraxofusp followed by allo-HCT for better patient outcomes.

Badikyan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark